{"title":"Short bowel syndrome-associated intestinal failure: diagnosis and prognosis.","authors":"John K DiBaise","doi":"10.1080/17474124.2026.2646296","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Short bowel syndrome is characterized by severe intestinal malabsorption of macronutrients, micronutrients, fluid, and electrolytes. As such, short bowel syndrome often results in permanent need of parenteral support, that is, intestinal failure. To optimize patient outcomes, it is important to establish precise definitions of short bowel syndrome and intestinal failure. Classifying those with SBS can provide useful prognostic, risk and therapeutic implications.</p><p><strong>Areas covered: </strong>This narrative review will focus on the diagnosis and prognosis of this rare condition. A literature search was performed utilizing PubMed and reviewed references from applicable manuscripts primarily between 2000 and September 2025.</p><p><strong>Expert opinion: </strong>Short bowel syndrome in adults is a clinical malabsorptive syndrome associated with having <200 cm of residual small bowel in continuity, measured from the duodenojejunal flexure. Intestinal failure is the reduction of gut function below the minimum required for the absorption of macronutrients and/or water and electrolytes, thereby requiring parenteral support to maintain health and/or growth. The remaining small bowel length and segment, and health of the remnant bowel have important prognostic implications. Care gaps exist regarding the diagnosis and management of this condition and future efforts should address these disparities in order to provide optimal care to these patients.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"313-323"},"PeriodicalIF":3.3000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2026.2646296","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Short bowel syndrome is characterized by severe intestinal malabsorption of macronutrients, micronutrients, fluid, and electrolytes. As such, short bowel syndrome often results in permanent need of parenteral support, that is, intestinal failure. To optimize patient outcomes, it is important to establish precise definitions of short bowel syndrome and intestinal failure. Classifying those with SBS can provide useful prognostic, risk and therapeutic implications.
Areas covered: This narrative review will focus on the diagnosis and prognosis of this rare condition. A literature search was performed utilizing PubMed and reviewed references from applicable manuscripts primarily between 2000 and September 2025.
Expert opinion: Short bowel syndrome in adults is a clinical malabsorptive syndrome associated with having <200 cm of residual small bowel in continuity, measured from the duodenojejunal flexure. Intestinal failure is the reduction of gut function below the minimum required for the absorption of macronutrients and/or water and electrolytes, thereby requiring parenteral support to maintain health and/or growth. The remaining small bowel length and segment, and health of the remnant bowel have important prognostic implications. Care gaps exist regarding the diagnosis and management of this condition and future efforts should address these disparities in order to provide optimal care to these patients.
期刊介绍:
The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.